Prospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 26, 2022; 10(6): 1834-1842
Published online Feb 26, 2022. doi: 10.12998/wjcc.v10.i6.1834
Superior pancreatic lymphadenectomy with portal vein priority via posterior common hepatic artery approach in laparoscopic radical gastrectomy
Yu-Jia Zhang, Rong-Chao Xiang, Jun Li, Yong Liu, Si-Ming Xie, Liang An, Hua-Lin Li, Gang Mai
Yu-Jia Zhang, Rong-Chao Xiang, Jun Li, Yong Liu, Si-Ming Xie, Liang An, Hua-Lin Li, Gang Mai, Department of General Surgery, Deyang City People's Hospital, Deyang 618000, Sichuan Province, China
Author contributions: Zhang YJ drafted the manuscript, and assisted with data analysis; Xiang RC participated in design and oversight of the study, and was involved with data collection; Li J participated in design of the study, and was involved with data collection; Liu Y was involved with data collection, and assisted with data analysis; Xie SM drafted the manuscript, and assisted with data analysis; An L and Li HL participated in study design and performed statistical analysis; Mai G participated in design of the study, was involved with data collection; all authors read and approved the final manuscript.
Institutional review board statement: The study has been approved by the ethics committee of the Deyang City People’s Hospital.
Clinical trial registration statement: The current study has not been registered, as the procedures of laparoscopic gastrectomy is a routine treatment of gastric cancers.
Informed consent statement: A waiver of informed consent was obtained, since the data were analyzed from the electronic medical record and reported without personal identifiers.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: Can be requested via contacting with the corresponding author.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gang Mai, MD, Chief Doctor, Department of General Surgery, Deyang City People's Hospital, No. 173 North Taishan Road, Deyang 618000, Sichuan Province, China. maigang68@hotmail.com
Received: July 27, 2021
Peer-review started: July 27, 2021
First decision: October 3, 2021
Revised: October 16, 2021
Accepted: January 17, 2022
Article in press: January 17, 2022
Published online: February 26, 2022
Processing time: 211 Days and 7.3 Hours
Core Tip

Core Tip: D2 radical operation has been the standard treatment of gastric cancer. One in 10 advanced gastric cancer patients had lymph node metastasis at station 8p, but D2 lymphadenectomy (LND) remains technically difficult. The new superior pancreatic LND with portal vein priority via the posterior common hepatic artery approach achieved safe removal of 8p lymph nodes.